Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants

作者：Subrata Chowdhury, Joe Veyhl, Fatima Jessa, Olena Polyakova, Ahmed Alenzi, Christina MacMillan, Ranju Ralhan, Paul G. Walfish · 发表于：Oncotarget · 年份：2016 · DOI：10.18632/oncotarget.8698 · 被引用次数：202 · 研究领域：Thyroid Cancer Diagnosis and Treatment、Ferroptosis and cancer prognosis、S100 Proteins and Annexins

// Subrata Chowdhury 1 , Joe Veyhl 1 , Fatima Jessa 1 , Olena Polyakova 1, 7 , Ahmed Alenzi 1, 7 , Christina MacMillan 3, 4 , Ranju Ralhan 1, 2, 3, 4, 5, 6 , Paul G. Walfish 1, 2, 3, 4, 7 1 Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Mount Sinai Hospital, Toronto, Ontario, Canada 2 Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Department of Otolaryngology-Head and Neck Surgery Program, Mount Sinai Hospital, Toronto, Ontario, Canada 3 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada 4 Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada 5 Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada 6 Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada 7 Department of Medicine, Endocrine Division, Mount Sinai Hospital and University of Toronto Medical School, Toronto, Ontario, Canada Correspondence to: Paul G. Walfish, email: pwalfish@mtsinai.on.ca Ranju Ralhan, email: rralhan@mtsinai.on.ca Keywords: thyroid cancer, benign nodule, programmed death-ligand 1, protein biomarkers, subcellular localization Received: March 23, 2016 Accepted: March 26, 2016 Published: April 12, 2016 ABSTRACT Programmed death-ligand 1(PD-L1) expression on tumor cells is emerging as a potential predictive biomarker in anti-PD-L1 directed cancer immunotherapy. We analyzed PD-L1 expression in pa...